DeepPath

DeepPath is a digital pathology company that utilizes deep learning algorithms to analyze histopathology images for cancer diagnosis and treatment planning. The company's technology automates the classification of lung cancer subtypes and predicts molecular mutations and biomarker expressions, such as PD-L1, directly from standard H&E stained slides. By integrating AI into the pathology workflow, DeepPath provides clinicians with rapid, reproducible, and objective data to guide immunotherapy and targeted treatments. The platform is designed to reduce the workload of pathologists while increasing diagnostic precision in oncology. Originally spun out of NYU Langone Health, the company has established itself as a pioneer in image-based molecular prediction. DeepPath was acquired by Aiforia Technologies in 2022 to enhance their clinical AI offerings for lung cancer.